X4 Pharmaceuticals (NASDAQ:XFOR) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS

X4 Pharmaceuticals (NASDAQ:XFOR) released its quarterly earnings results on Tuesday. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.14, Zacks reports. X4 Pharmaceuticals had a negative net margin of 279.86% and a negative return on equity of 343.67%. The company had revenue of $2.57 million during the quarter, compared to the consensus estimate of $1.68 million.

X4 Pharmaceuticals Stock Up 1.8%

NASDAQ:XFOR traded up $0.08 during trading hours on Wednesday, reaching $4.31. 24,597 shares of the company traded hands, compared to its average volume of 482,904. The business’s 50-day moving average price is $3.66 and its two-hundred day moving average price is $3.61. The stock has a market capitalization of $376.43 million, a P/E ratio of -0.42 and a beta of 0.43. X4 Pharmaceuticals has a 1 year low of $1.35 and a 1 year high of $9.56. The company has a current ratio of 5.65, a quick ratio of 5.48 and a debt-to-equity ratio of 1.23.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research report on Monday, December 29th. Guggenheim initiated coverage on X4 Pharmaceuticals in a research report on Monday, March 9th. They set a “buy” rating and a $12.00 price target on the stock. Zacks Research cut X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 26th. Wall Street Zen downgraded X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, November 30th. Finally, Stifel Nicolaus set a $10.00 price objective on X4 Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, December 5th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, X4 Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $28.88.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC purchased a new position in X4 Pharmaceuticals in the fourth quarter worth about $90,000. Susquehanna Portfolio Strategies LLC bought a new position in shares of X4 Pharmaceuticals during the 4th quarter valued at $173,000. Man Group plc purchased a new stake in X4 Pharmaceuticals during the fourth quarter valued at $97,000. Balyasny Asset Management L.P. bought a new position in X4 Pharmaceuticals in the fourth quarter valued at about $258,000. Finally, Braidwell LP bought a new position in X4 Pharmaceuticals in the fourth quarter valued at about $13,476,000. 72.03% of the stock is currently owned by institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.